Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:NIPH's Return-on-Tangible-Equity is ranked better than 83.13% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs CAI:NIPH: 24.41
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Equity Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Equity Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
Return-on-Tangible-Equity
0.00
16.92
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 25.78% mean?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a Return-on-Tangible-Equity of 25.78% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. This is 52% above median its historical median of 16.92. Over the past decade, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Equity has ranged from 16.92 to 24.41. According to the industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #152 out of 901 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Equity too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Equity of 25.78% is 52% above median its 10-year median of 16.92. Over the past 10 years, this metric has ranged from a low of 16.92 to a high of 24.41. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 25.78% is 226.3% above this industry median. Based on the distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #152 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #152 out of 901 companies for Return-on-Tangible-Equity. This places El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 25.78% is 226.3% above this benchmark. Historically, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's own Return-on-Tangible-Equity has ranged from 16.92 to 24.41 over the past decade. While the company's 10-year median is 16.92 vs. the industry median of 7.90, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Equity of 25.78% is 226.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Equity is 25.78%, which is 52% above median its own 10-year median of 16.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current Return-on-Tangible-Equity of 25.78%. The current Return-on-Tangible-Equity is 25.78%, which is 52% above median its 10-year median of 16.92 and 226.3% above the Drug Manufacturers industry median of 7.90. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current Return-on-Tangible-Equity is 25.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Business Description
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
